- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01515761
POsition of Leads in Advanced heaRt Failure: the POLAR Study (POLAR)
23 januari 2012 uppdaterad av: Sergio Thal, M.D.
POsition of Leads in Advanced heaRt Failure: the POLAR Study - A 6 Month, Observational, Mult-centered, Blinded, Randomized Study to Determine if Lead Positioning in the Lateral Wall of LV in Patients Meeting Criteria for CRT Plays a Role in Determining Myocardial Function and Affect the Severity of Mitral Regurgitation
The primary objective is to determine if lead positioning in the lateral wall of the left ventricle in patients meeting criteria for cardiac resynchronization therapy plays a role in determining myocardial function and affects the severity of mitral regurgitation.
Studieöversikt
Status
Okänd
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a 6 month, multi-centered, blinded, randomized study.
Approximately 60 patients will join this study.
Two groups, based on lead position, will be studied with thirty (30) patients randomized into each group.
Studietyp
Interventionell
Inskrivning (Förväntat)
60
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Arizona
-
Tucson, Arizona, Förenta staterna, 85723
- Rekrytering
- Southern Arizona VA Health Care System
-
Kontakt:
- Sergio Thal, M.D.
- Telefonnummer: 4624 520-792-1450
- E-post: sergio.thal@va.gov
-
Kontakt:
- Elizabeth Juneman, M.D.
- Telefonnummer: 4624 520-792-1450
- E-post: elizabeth.juneman@va.gov
-
Huvudutredare:
- Sergio Thal, M.D.
-
Underutredare:
- Elizabeth Juneman, M.D.
-
Underutredare:
- Hoang Thai, M.D.
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40502
- Rekrytering
- Lexington VA Medical Center
-
Kontakt:
- Samy Elayi, M.D.
- Telefonnummer: 859-233-4511
-
Huvudutredare:
- Samy Elayi, M.D.
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Subject meets the general indications for an implantable cardioverter defibrillator (ICD) with LV systolic function ≤ 35% as defined by echocardiography.
- Subject has moderate or severe heart failure, defined as NYHA Class III-IV for at least 90 days prior to enrollment.
- Subject has optimal pharmacological heart failure therapy for at least 30 days prior to enrollment.
- Subject has a 12-lead electrocardiogram (ECG) obtained no more than 90 days prior to enrollment documenting a sinus rate > 50 bpm and PR interval < 320 ms measured from any two leads.
- 12 lead ECG with left bundle brunch block morphology and a QRS duration of at least 120 msec.
- Subject has creatinine < 2.5 mg/dL obtained no more than 30 days prior to enrollment.
- Subject has left ventricular ejection fraction < 35% by echocardiogram no more than 1 year prior to enrollment.
- Subject is willing and capable of undergoing a device implant and participating in all testing associated with this clinical investigation.
- Subject has a life expectancy of more than 180 days, per physician discretion.
- Subject is age 18 or above, or of legal age to give informed consent specific to state and national law.
Exclusion Criteria:
- Subject has right bundle branch block morphology on a 12-lead ECG obtained no more than 90 days prior to enrollment.
- Subject had previous cardiac resynchronization therapy, a previous coronary venous lead, or meets the general indications for anti-bradycardia pacing defined as ventricular pacing > 40% by pacemaker interrogation.
- Subject has a neuromuscular, orthopedic, or other non-cardiac condition that prevents normal, unsupported walking.
- Subject has an atrial tachyarrhythmia that is permanent (i.e., does not terminate spontaneously and cannot be terminated with medical intervention) or persistent (i.e., can be terminated with medical intervention, but does not terminate spontaneously) within 30 days prior to enrollment.
- Subject currently requires dialysis.
- Subject has severe chronic obstructive pulmonary disease (COPD), defined as FEV1/FVC < 60%, or as defined by a physician.
- Subject has had a myocardial infarction within 30 days prior to enrollment or coronary artery disease (CAD) in which surgical or percutaneous correction was performed within 30 days prior to enrollment.
- Subject has hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g., amyloidosis, sarcoidosis).
- Subject is on IV inotropic agents.
- Subject has any mitral valve prosthesis, or a mechanical aortic or tricuspid prosthesis
- Subject is enrolled in any concurrent study, without Medtronic written approval, which may confound the results of this study.
- Subject is pregnant or planning to get pregnant.
- Subject requires oxygen for medical reasons other than CHF.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Postero-lateral
Left ventricular lateral wall lead position
|
A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.
|
|
Aktiv komparator: Antero-lateral
Left ventricular lateral wall lead position
|
A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Change (reduction) in left ventricular end systolic volume (LVESV)
Tidsram: 3 and 6 months
|
3 and 6 months
|
|
Change in 6 minute walk tests
Tidsram: 6 weeks, 3 and 6 months
|
6 weeks, 3 and 6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Myocardial performance as measured by myocardial performance index (MPI)
Tidsram: 6 months
|
6 months
|
|
|
Papillary muscle velocity as determined by tissue doppler
Tidsram: 6 months
|
6 months
|
|
|
Progression of mitral regurgitation
Tidsram: 6 months
|
as measured by regurgitant volume, mitral regurgitation fraction and effective regurgitant orifice area
|
6 months
|
|
Minnesota living heart failure survey
Tidsram: 6 weeks, 3 and 6 months
|
6 weeks, 3 and 6 months
|
|
|
Chronic heart failure hospitalizations
Tidsram: Monitored during study participation ~ 6 months
|
Monitored during study participation ~ 6 months
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Sergio Thal, M.D., Southern Arizona VA Health Care System
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 september 2010
Primärt slutförande (Förväntat)
1 mars 2013
Studieregistreringsdatum
Först inskickad
12 januari 2012
Först inskickad som uppfyllde QC-kriterierna
23 januari 2012
Första postat (Uppskatta)
24 januari 2012
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
24 januari 2012
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
23 januari 2012
Senast verifierad
1 januari 2012
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- PIIT1A
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .